We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

6869:HKEXYangtze Optical Fibre and Cable Joint Stock Ltd Co Class H Analysis

Data as of 2026-03-14 - not real-time

HK$159.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Yangtze Optical Fibre is trading well above its short‑term moving average, with momentum indicators pointing to an overbought condition and a bearish MACD divergence despite an overall bullish trend and rising volume. Technical signals suggest short‑term caution as the price may face resistance near recent highs, while the RSI remains elevated, hinting at potential pull‑back.
Fundamentally, the stock appears dramatically overvalued; discounted cash‑flow analysis places fair value far below the current market level, and valuation multiples dwarf both industry averages and historical norms. The company’s modest dividend yield is offset by high leverage and thin profitability, raising questions about dividend sustainability. Recent corporate actions, including a new H‑share placement to fund global expansion and governance restructuring, provide a catalyst for growth but also add execution risk. Overall, the juxtaposition of strong technical momentum with stark valuation disconnect suggests a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price above short‑term average but RSI overbought
  • Bearish MACD histogram indicating weakening momentum
  • Increasing volume supporting current trend

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Severe valuation premium relative to DCF fair value
  • High debt load and low profitability margins
  • Growth potential from global expansion funded by new H‑shares

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Valuation gap unlikely to close without major earnings uplift
  • Regulatory and geopolitical headwinds for Chinese tech firms
  • Sustaining dividend payments challenged by weak returns on equity

Key Metrics & Analysis

Financial Health

Revenue Growth16.30%
Profit Margin4.16%
P/E Ratio178.7
ROE3.89%
ROA2.00%
Debt/Equity64.08
P/B Ratio8.9
Op. Cash FlowHK$2.9B
Free Cash FlowHK$1.0B
Industry P/E33.7

Technical Analysis

TrendBullish
RSI63.6
SupportHK$105.60
ResistanceHK$206.80
MA 20HK$139.78
MA 50HK$94.92
MA 200HK$49.80
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueHK$17.00
Target PriceHK$52.77
Upside/Downside-66.81%
GradeOvervalued
TypeGrowth
Dividend Yield0.18%

Risk Assessment

Beta0.75
Volatility126.34%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.